Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mallory Kowalski

Nurse Practitioner, Family Newark, DE Nurse Practitioner

NPI 1356746382 CMS profile 10523223

620 Stanton Christiana Rd Ste 202, Newark, DE 19713

Open in the dashboard

General payments

$6,628

209 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mallory Kowalski of Newark, DE is reported in the CMS Open Payments database as having received $6,628 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $665 40
2024 General $769 51
2023 General $2,831 51
2022 General $2,032 43
2021 General $332 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mallory Kowalski
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Mallory Kowalski were reported at $665. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Mallory Kowalski Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $332 $124 $35–$379 $132
2022 $2,032 $141 $44–$430 $149
2023 $2,831 $154 $49–$476 $160
2024 $769 $165 $51–$504 $164
2025 $665 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $4,064 36 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $752 60 payments
  3. Collegium Pharmaceutical, Inc. $599 45 payments
  4. Scilex Pharmaceuticals Inc. $272 14 payments
  5. AbbVie, Inc. $227 10 payments
  6. Biodelivery Sciences International, Inc. $126 13 payments
  7. Valinor Pharma, LLC $84 5 payments
  8. Vertex Pharmaceuticals Incorporated $82 4 payments
  9. CutisPharma, Inc. $78 2 payments
  10. GRT US Holding, Inc. $72 4 payments
  11. Other $273 16 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,107 197 payments
  2. Travel and Lodging $2,414 10 payments
  3. Education $108 2 payments
Products named General payments · program years 2021–2025
  1. SYNCHROMEDII $3,856 32 payments
  2. RELISTOR Gastroenterology $535 43 payments
  3. RELISTOR Gastroenterology $400 34 payments
  4. BELBUCA Opioid Analgesic $398 30 payments
  5. ZTLido $272 14 payments
  6. INTELLIS ADAPTIVESTIM $207 4 payments
  7. XTAMPZA $201 15 payments
  8. UBRELVY $160 7 payments
  9. BELBUCA Chronic Pain $126 13 payments
  10. QULIPTA $125 5 payments
  11. Other $615 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

4,477

Median for Nurse Practitioner: 389

Drug cost

$514,828

Median for Nurse Practitioner: $21,885

Branded share of claims

35.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 126 $120,436
Oxycontin Oxycodone Hcl Brand 97 $58,905
Relistor Methylnaltrexone Bromide Brand 18 $45,949
Xtampza Er Oxycodone Myristate Brand 86 $45,678
Mounjaro Tirzepatide Brand 30 $31,529
Ozempic Semaglutide Brand 17 $26,357
Buprenorphine Generic 102 $24,763
Nucynta Tapentadol Hcl Brand 13 $18,983
Nurtec Odt Rimegepant Sulfate Brand 18 $17,835
Oxycodone Hcl Generic 804 $14,692

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$126,061

Of which drugs: $142

Medicare patients

196

Average age 69

Services billed

2,212

150 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 47%
Diabetes 44%
Chronic kidney disease 33%
Ischemic heart disease 30%
COPD 21%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 25 258 $139

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $333
$333 18 —
BELBUCA
  • Collegium Pharmaceutical, Inc. $124
$124 126 —
ZTLido
  • Scilex Pharmaceuticals Inc. $63
$63 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $34
$34 86 —
MOVANTIK
  • Valinor Pharma, LLC $32
$32 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record